The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pneumonitis (interstitial lung disease/ILD)
Publications
Interstitial pneumonitis associated with the immunomodulatory drugs thalidomide and lenalidomide.
International journal of hematology 2012 Feb;95;223-4 — 2012 Feb — 223-4
Reversible pulmonary toxicity due to lenalidomide.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2012 Jun;18;284-6 — 2012 Jun — 284-6
Thalidomide induced nonspecific interstitial pneumonia in patient with relapsed multiple myeloma.
The Korean journal of internal medicine 2010 Dec;25;447-9 — 2010 Dec — 447-9
A case of lenalidomide-induced hypersensitivity pneumonitis.
Onkologie 2010;33;249-52 — 2010 — 249-52
Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: No recurrence with subsequent lenalidomide therapy.
American journal of hematology 2009 Oct;84;698-9 — 2009 Oct — 698-9
Thalidomide-induced pneumonitis.
European journal of internal medicine 2008 Nov;19;e57-8 — 2008 Nov — e57-8
Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide.
Chest 2007 May;131;1572-4 — 2007 May — 1572-4
[Lung toxicity due to thalidomide].
Archivos de bronconeumologia 2003 May;39;240 — 2003 May — 240